Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | EED | O75530 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757020 | 0.85 | CYP11B2 (0.38) | MAPK14MAPK11 | |
| SCHEMBL5741788 | 0.79 | MAPK14 (0.42) | MAPK14MAPK11KDM1ADRD2 | |
| SCHEMBL5740394 | 0.77 | MAPK11 (0.34) | MAPK14MAPK11KDM1ADRD2 | |
| SCHEMBL5740316 | 0.76 | MAPK14 (0.39) | MAPK14MAPK11DRD2 | |
| SCHEMBL5741723 | 0.69 | GSK3B (0.54) | — | |
| SCHEMBL6364470 | 0.69 | ADORA2A (0.42) | MAPK14MAPK11KDM1AALDH1A1 | |
| SCHEMBL5901913 | 0.68 | PRKCI (0.64) | MAPK14CSNK1D | |
| SCHEMBL5901909 | 0.68 | PRKCI (0.64) | MAPK14CSNK1D | |
| SCHEMBL12902085 | 0.61 | HTR2B (0.60) | ALDH1A1DRD2 | |
| SCHEMBL30232571 | 0.60 | MAPK11 (0.51) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049318-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050020592-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020592-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | MAPK14 2472/4885MAPK11 1547/4885KDM1A 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.